Financial News Archive

Tarsus reported Q2 2026 net product sales of $173.9 million for XDEMVY and updated full-year guidance to $685-705 million, while advancing a pending a...

The BDC reported Q2 2026 NII of $0.41 per share and declared a Q3 distribution of $0.38 per share. Additionally, the company redeemed a CLO and issued...

Cogent reported a Q2 2026 loss of $9.2 million and a decline in service revenue despite gains from selling data centers and purchasing its own secured...

Sotera Health beat earnings expectations across all metrics and raised its revenue and EBITDA guidance for FY 2026....

Driven Brands reported $507.4M in Q2 revenue, matching or beating prior year results across its segments due to strong system sales....

PBGENE-HBV achieved first biopsy evidence of cccDNA elimination, while the company reported Q2 2026 results and a cash balance of $112.4 million....

FrontView REIT reported strong Q2 2026 results with a 64.7% AFFO payout ratio and looks to grow funds from operations per share and net investments in...

Harrow will acquire TYVRAYA nasal spray from Viatris for up to $100 million in cash and contingent milestones to expand its ophthalmic portfolio....

Immunovant reported $797.8M in cash and non-GAAP losses, with key topline data for CLE and D2T RA expected in late 2026. Only 90% of data provided for...

Fiserv reported decreased GAAP and adjusted revenue and EPS for Q2 2026, driven by segment-specific declines; the company updated its 2026 outlook ami...

Aclaris Therapeutics announced full Phase 1a trial results for ATI-052 and affirmed timelines for upcoming clinical data readouts and a Phase 2b progr...

Roivant reported Q1 2026 results, highlighting a $3.9B cash balance and a settlement with Moderna....

Institutional holdings report (13F-HR) filed by HS Management Partners, LLC....

Xeris Biopharma reported $92.1M in Q2 2026 revenue, up 29% year-over-year, driving a revision of full-year guidance to $385M-$390M as Recorlev sales s...

Sionna Therapeutics has voluntarily withdrawn its New Drug Application for STX001, which had a Prescription Drug User Fee Act date, to conduct a strat...

Ironwood Pharmaceuticals raised total revenue and adjusted EBITDA guidance for 2026, citing strong LINZESS performance, while also repaying convertibl...

Tarsus Pharmaceuticals, Inc. issued a pre-funded warrant to purchase up to a total of shares of common stock with an exercise price of $0.0001. The wa...

CareCloud reported 16% revenue growth for Q2 2026 and nine consecutive quarters of GAAP net income, driven by AI investments and the acquisition of Em...

Bausch+Lomb appointed four directors including Thomas Appio and Robert Chersi, replacing previous board members; Q2 revenue increased 9%....

REGENXBIO reported strong second-quarter results, announcing the initiation of RGX-202 BLA filing and up to ~2H 2027 catalyst expectations, extending ...